Category: Sleep Treatments

Sleep Treatments

Latest

FDA Grants Orphan Drug Designation to Once-Nightly Oxybate for Idiopathic Hypersomnia

The FDA has granted Orphan Drug Designation to Tris Pharma’s TRN-257, an investigational once-nightly, low-sodium oxybate therapy for the treatment of idiopathic hypersomnia. The designation recognizes the potential for this formulation to reduce nocturnal treatment burdens while offering a lower-sodium alternative for patients requiring long-term care.

Insomnia Devices

Latest

Nexalin Technology Secures US Patent for Deep-Brain Stimulation Targeting Insomnia

Nexalin Technology has secured a US patent for its Deep Intracranial Frequency Stimulation (DIFS) platform, protecting its noninvasive, in-home treatment method for insomnia, anxiety, and depression through 2042. The patent reinforces the company’s strategy to expand physician-supervised, drug-free neurostimulation care via its virtual clinic model.